Kura Oncology's Ziftomenib Shows Strong Efficacy in AML Combination Therapy
Event summary
- Kura Oncology and Kyowa Kirin published updated results from the KOMET-007 trial in Blood, showing 87% ORR and 70% CRc in venetoclax-naïve patients with R/R NPM1-m AML.
- The combination of ziftomenib with venetoclax and azacitidine demonstrated deep molecular responses, with 75% of CRc responders achieving central MRD negativity.
- The triplet combination was well tolerated, with low rates of differentiation syndrome (3%) and QTc prolongation observed.
- Kura Oncology is continuing to evaluate ziftomenib across multiple combination regimens and treatment settings, including ongoing pivotal KOMET-017 Phase 3 trials.
The big picture
The publication of these results underscores the growing importance of combination therapies in treating relapsed/refractory AML. Kura Oncology's focus on menin inhibition with ziftomenib positions it as a key player in the precision oncology space, particularly for patients with NPM1-mutated AML. The favorable safety profile and deep molecular responses observed in the trial highlight the potential for ziftomenib to become a standard of care in this indication.
What we're watching
- Clinical Validation
- How the robust efficacy data from the KOMET-007 trial will impact the regulatory approval process for ziftomenib in combination therapies.
- Market Positioning
- Whether Kura Oncology can establish ziftomenib as a backbone therapy in NPM1-mutant AML, competing with existing treatments.
- Combination Strategies
- The pace at which Kura Oncology advances ziftomenib-based combinations across different AML patient populations and treatment settings.